Munro Partners Purchases 14,730 Shares of Boston Scientific Corporation $BSX

Munro Partners lifted its position in Boston Scientific Corporation (NYSE:BSX) by 1.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,256,810 shares of the medical equipment provider’s stock after purchasing an additional 14,730 shares during the quarter. Boston Scientific accounts for approximately 3.1% of Munro Partners’ holdings, making the stock its 13th biggest holding. Munro Partners owned approximately 0.08% of Boston Scientific worth $119,837,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in BSX. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth about $26,000. Swiss RE Ltd. acquired a new position in Boston Scientific during the 4th quarter worth about $26,000. Colonial Trust Co SC lifted its position in Boston Scientific by 502.2% during the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock worth $27,000 after buying an additional 231 shares in the last quarter. Bangor Savings Bank lifted its position in Boston Scientific by 94.7% during the 4th quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 142 shares in the last quarter. Finally, Board of the Pension Protection Fund acquired a new position in Boston Scientific during the 4th quarter worth about $29,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Barclays reduced their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, May 28th. Stifel Nicolaus set a $75.00 price target on shares of Boston Scientific in a research report on Wednesday, May 27th. The Goldman Sachs Group set a $71.00 target price on shares of Boston Scientific in a research report on Thursday, May 28th. UBS Group cut their target price on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Finally, Raymond James Financial restated an “outperform” rating and set a $88.00 target price (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.08.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig bought 3,580 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger purchased 2,250 shares of the firm’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This represents a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 9,800 shares of company stock valued at $554,012. 0.34% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

Shares of BSX stock opened at $46.69 on Tuesday. The stock has a 50-day moving average of $56.05 and a 200-day moving average of $74.40. Boston Scientific Corporation has a one year low of $45.99 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. The stock has a market cap of $69.39 billion, a PE ratio of 19.53, a price-to-earnings-growth ratio of 0.89 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the prior year, the business earned $0.75 EPS. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current year.

Boston Scientific declared that its Board of Directors has authorized a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s leadership believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.